Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03538743 · ClinicalTrials.gov registry record · Phase 1
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
A Phase 1 study of Type 2 Diabetes Mellitus, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
- 4
- Study locations
NCT03538743: Completed Phase 1 study of Type 2 Diabetes Mellitus, sponsored by Pfizer.
NCT03538743 is a Phase 1 study of Type 2 Diabetes Mellitus that has completed, run by Pfizer. The registered enrollment target is 98 participants, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03538743, a Phase 1 study of Type 2 Diabetes Mellitus, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.
Primary Outcome
Treatment-related adverse event (AE) was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first do
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-06882961
Study Locations (4)
Florida
- Qps-Mra, Llc - South Miami
- Qps-Mra,Llc - South Miami
California
- Anaheim Clinical Trials, LLC - Anaheim
Kansas
- Altasciences Clinical Kansas, Inc. - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2018-06-25 |
| Est. Completion | 2019-06-10 |
| Phase | Phase 1 |
What the finished NCT03538743 record still lists
NCT03538743 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03538743 reports a single indexed study location in Florida, California, Kansas.
Frequently Asked Questions
What is clinical trial NCT03538743 about?
NCT03538743 is a clinical study titled "4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes". This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.
What is the current status of trial NCT03538743?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2018-06-25. Estimated completion is 2019-06-10.
What conditions does trial NCT03538743 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT03538743?
The interventions under investigation include: Placebo (DRUG), PF-06882961 (DRUG).
Who is sponsoring clinical trial NCT03538743?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03538743 being conducted?
This trial has 4 study locations across California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03538743's enrollment target sits among peer trials
98 56th of 130 higher than 75 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
COMPLETED · Phase 1
-
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
COMPLETED · Phase 1
-
A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol
COMPLETED · Phase 1
-
Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI